vimarsana.com

Latest Breaking News On - Breath therapeutics - Page 1 : vimarsana.com

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

Amneal Pharmaceuticals, Inc. today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group , for IPX203 in the European Union, United.

United statesMidi pyréesUnited kingdomFrank weberChintu patelKnight therapeutics incAmneal groupParkinson foundationAmneal pharmaceuticals incExchange commissionDrug administrationEuropean unionAmneal pharmaceuticalsZambon biotechCo chief executive officersChief executive officer

Zambon Presents Results from the Two Phase 3 PROMIS Studies of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis at World Bronchiectasis Conference 2023

Data show inhalation via the I-neb Adaptive Aerosol Delivery System of colistimethate sodium (CMS) results in reduction of pulmonary exacerbations in.

New zealandUnited kingdomNew yorkUnited statesCharles haworthPrnewswire zambonIlaria villaLindsay roccoJames chalmersPaola castellaniDevelopment programElixir health public relationsProfessor of respiratory researchUniversity of dundeeI neb adaptive aerosol delivery systemFast track

Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)

/PRNewswire/ Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people s health and the quality of patients .

United statesPrnewswire zambonPaola castellaniLindsay roccoIlaria villaPharma gmbElixir health public relationsDrug administrationEuropean medicines agencyPivotal phaseLiposomal cyclosporineOrphan drug designationFast trackBronchiolitis obliterans syndromeObliterans syndromeZambon spa

Adrenomed appoints Dr Stephan Witte as Chief Medical Officer

EQS-News: Adrenomed AG / Key word(s): PersonnelAdrenomed appoints Dr. Stephan Witte as Chief Medical Officer 01.02.2023 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer Hennigsdorf/Berlin (Germany),.

Baden wübergRichard jonesHelion pharmaStephan witteEva bauer juliaMc servicesEuropean centerDistribution servicesHead of clinical developmentRegulatory affairs at inotremUniversity of konstanzChief medical officerVice president clinical scienceAtriva therapeuticsVice president clinical trialsBreath therapeutics

DelveInsight Business Research, LLP: Bronchiolitis Obliterans Syndrome Market To Project High at a 4 26% CAGR in the 7MM During the Study Period [2018-2030], Evaluates DelveInsight

Currently, major driving factors for Bronchiolitis Obliterans Syndrome market include development of potential therapies such as Zambon's Phase III asset, Liposomal cyclosporine A, under clinical

United statesFrance generalUnited kingdomShruti thakurChiesi farmaceuticiPrnewswire delveinsightDima italiaMereo biopharmaDelveinsight bronchiolitis obliteransKoninklijke philipsStates bronchiolitis obliteransGenentech incyte corporationIntersurgical ltdStryker corporationLepu medical technologyBusiness consulting service

vimarsana © 2020. All Rights Reserved.